IU Health Krannert Personalized Medicine Study
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/27/2018 |
| Start Date: | November 2016 |
| End Date: | November 2018 |
| Contact: | Rolf Kreutz, MD |
| Email: | rkreutz@iu.edu |
| Phone: | 3179620500 |
IU Health Krannert Personalized Medicine Study - Influencing Prescriber Behavior for the Use of Clopidogrel
Randomized controlled study to examine physician use of pharmacogenetic information in
patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).
patients receiving antiplatelet medication after percutaneous coronary intervention (PCI).
The study will randomize patients who have completed PCI and who are prescribed dual
antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will
be performed and a standard therapy arm without genetic testing. The study will examine the
impact of pharmacogenetic testing on physician medication choice and clinical outcomes.
antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will
be performed and a standard therapy arm without genetic testing. The study will examine the
impact of pharmacogenetic testing on physician medication choice and clinical outcomes.
Inclusion Criteria:
- Patients with ischemic heart disease, who are prescribed dual antiplatelet therapy
after percutaneous coronary intervention (PCI). Enrollment has to occur during index
hospitalization or during outpatient visit for cath lab procedure.
Exclusion Criteria:
- Pregnant or breastfeeding.
- Unwilling or unable, in the opinion of the investigator, to comply with instructions
on prescribed medicines.
- Prior known allergy or intolerance to clopidogrel.
We found this trial at
1
site
Click here to add this to my saved trials
